Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LSS | P48449 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | ESRRG | P62508 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3078338 | 0.93 | PLA2G7 (0.39) | NR1I2PLA2G7LSSESR1ESR2 | |
| SCHEMBL3468515 | 0.88 | CYP19A1 (0.46) | NR1I2GAAESR1ESR2ESRRG | |
| SCHEMBL3081636 | 0.88 | GAA (0.52) | NR1I2GAALSSESR1ESR2 | |
| SCHEMBL3082856 | 0.86 | NR1I2 (0.42) | NR1I2PLA2G7GAALSSESR1 | |
| SCHEMBL3075680 | 0.84 | LTA4H (0.46) | PLA2G7LSS | |
| SCHEMBL3068903 | 0.82 | PLA2G7 (0.38) | PLA2G7GAAESR1ESR2PTPN7 | |
| SCHEMBL3069744 | 0.82 | LMNA (0.42) | GAAMAOBALDH1A1 | |
| SCHEMBL13095715 | 0.82 | PLA2G7 (0.36) | PLA2G7GAALSSESR1ESR2 | |
| SCHEMBL3081328 | 0.81 | GAA (0.45) | NR1I2GAAESR1ESR2ALDH1A1 | |
| SCHEMBL3468209 | 0.81 | ESR1 (0.42) | NR1I2ESR1ESR2ALDH1A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | claimed |
| EP-1891026-B1 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-07-14 | — | — | EP | claimed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | claimed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | claimed |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | disclosed |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | disclosed |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | disclosed |
| EP-1891026-B1 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | NR1I2 30/4885PLA2G7 808/4885GAA 3716/4885 |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | NR1I2 30/4885PLA2G7 808/4885GAA 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.